866-997-4948(US-Canada Toll Free)

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Oncology

No. of Pages : 569 Pages

This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler\'s Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler\'s Disease) and special features on late-stage and discontinued projects.

 

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

  • The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler\'s Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Multiple Myeloma (Kahler\'s Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Multiple Myeloma (Kahler\'s Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Multiple Myeloma (Kahler\'s Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

 

Reasons to buy

 

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler\'s Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler\'s Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Content

 

 

Table of Contents 2
Introduction 7
Multiple Myeloma (Kahler\'s Disease) Overview 8
Therapeutics Development 9
Multiple Myeloma (Kahler\'s Disease) - Therapeutics under Development by Companies 11
Multiple Myeloma (Kahler\'s Disease) - Therapeutics under Investigation by Universities/Institutes 20
Multiple Myeloma (Kahler\'s Disease) - Pipeline Products Glance 23
Multiple Myeloma (Kahler\'s Disease) - Products under Development by Companies 27
Multiple Myeloma (Kahler\'s Disease) - Products under Investigation by Universities/Institutes 36
Multiple Myeloma (Kahler\'s Disease) - Companies Involved in Therapeutics Development 38
Multiple Myeloma (Kahler\'s Disease) - Therapeutics Assessment 129
Drug Profiles 152
Multiple Myeloma (Kahler\'s Disease) - Recent Pipeline Updates 404
Multiple Myeloma (Kahler\'s Disease) - Dormant Projects 533
Multiple Myeloma (Kahler\'s Disease) - Discontinued Products 539
Multiple Myeloma (Kahler\'s Disease) - Product Development Milestones 540
 

Appendix 550

List of Table

 

Number of Products under Development for Multiple Myeloma (Kahler\'s Disease), H1 2014 27

Number of Products under Development for Multiple Myeloma (Kahler\'s Disease) - Comparative Analysis, H1 2014 28

Number of Products under Development by Companies, H1 2014 30

Number of Products under Development by Companies, H1 2014 (Contd..1) 31

Number of Products under Development by Companies, H1 2014 (Contd..2) 32

Number of Products under Development by Companies, H1 2014 (Contd..3) 33

Number of Products under Development by Companies, H1 2014 (Contd..4) 34

Number of Products under Development by Companies, H1 2014 (Contd..5) 35

Number of Products under Development by Companies, H1 2014 (Contd..6) 36

Number of Products under Development by Companies, H1 2014 (Contd..7) 37

Number of Products under Investigation by Universities/Institutes, H1 2014 39

Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 40

Comparative Analysis by Late Stage Development, H1 2014 41

Comparative Analysis by Clinical Stage Development, H1 2014 42

Comparative Analysis by Early Stage Development, H1 2014 43

Comparative Analysis by Unknown Stage Development, H1 2014 44

Products under Development by Companies, H1 2014 45

Products under Development by Companies, H1 2014 (Contd..1) 46

Products under Development by Companies, H1 2014 (Contd..2) 47

Products under Development by Companies, H1 2014 (Contd..3) 48

Products under Development by Companies, H1 2014 (Contd..4) 49

Products under Development by Companies, H1 2014 (Contd..5) 50

Products under Development by Companies, H1 2014 (Contd..6) 51

Products under Development by Companies, H1 2014 (Contd..7) 52

Products under Development by Companies, H1 2014 (Contd..8) 53

Products under Investigation by Universities/Institutes, H1 2014 54

Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 55

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Johnson & Johnson, H1 2014 56

Multiple Myeloma (Kahler\'s Disease) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 57

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Amgen Inc., H1 2014 58

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Eli Lilly and Company, H1 2014 59

Multiple Myeloma (Kahler\'s Disease) - Pipeline by GlaxoSmithKline plc, H1 2014 60

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Seattle Genetics, Inc., H1 2014 61

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Biotest AG, H1 2014 62

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Merck & Co., Inc., H1 2014 63

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Gamida Cell Ltd., H1 2014 64

Multiple Myeloma (Kahler\'s Disease) - Pipeline by BioLineRx, Ltd., H1 2014 65

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Amorfix Life Sciences Ltd., H1 2014 66

Multiple Myeloma (Kahler\'s Disease) - Pipeline by ZIOPHARM Oncology, Inc., H1 2014 67

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 68

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Novartis AG, H1 2014 69

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Nippon Kayaku Co., Ltd., H1 2014 70

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 71

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Sigma-Tau S.p.A., H1 2014 72

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 73

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 74

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Santaris Pharma A/S, H1 2014 75

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Celgene Corporation, H1 2014 76

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 77

Multiple Myeloma (Kahler\'s Disease) - Pipeline by XTL Biopharmaceuticals Ltd., H1 2014 78

Multiple Myeloma (Kahler\'s Disease) - Pipeline by MannKind Corporation, H1 2014 79

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Merck KGaA, H1 2014 80

Multiple Myeloma (Kahler\'s Disease) - Pipeline by 4SC AG, H1 2014 81

Multiple Myeloma (Kahler\'s Disease) - Pipeline by EntreMed, Inc., H1 2014 82

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Gentium S.p.A., H1 2014 83

Multiple Myeloma (Kahler\'s Disease) - Pipeline by AEterna Zentaris Inc., H1 2014 84

Multiple Myeloma (Kahler\'s Disease) - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2014 85

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Immunomedics, Inc., H1 2014 86

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Compugen Ltd., H1 2014 87

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Patrys Limited, H1 2014 88

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Curis, Inc., H1 2014 89

Multiple Myeloma (Kahler\'s Disease) - Pipeline by BioInvent International AB, H1 2014 90

Multiple Myeloma (Kahler\'s Disease) - Pipeline by JW Pharmaceutical Corporation, H1 2014 91

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Innate Pharma SA, H1 2014 92

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Transgene Biotek Limited, H1 2014 93

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Cellerant Therapeutics, Inc., H1 2014 94

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 95

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Chroma Therapeutics Ltd., H1 2014 96

Multiple Myeloma (Kahler\'s Disease) - Pipeline by CIMAB S.A., H1 2014 97

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 98

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Acceleron Pharma, Inc., H1 2014 99

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Priaxon AG, H1 2014 100

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Hutchison MediPharma Limited, H1 2014 101

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Vivolux AB, H1 2014 102

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Altor BioScience Corporation AB, H1 2014 103

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Coronado Biosciences, Inc., H1 2014 104

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Vaccinex, Inc., H1 2014 105

Multiple Myeloma (Kahler\'s Disease) - Pipeline by CanBas Co., Ltd., H1 2014 106

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Axelar AB, H1 2014 107

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Onconova Therapeutics, Inc., H1 2014 108

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Selexys Pharmaceuticals Corporation, H1 2014 109

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Immune System Therapeutics Ltd., H1 2014 110

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 111

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Enceladus Pharmaceuticals BV, H1 2014 112

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Immunocore Limited, H1 2014 113

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2014 114

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Pharma Mar, S.A., H1 2014 115

Multiple Myeloma (Kahler\'s Disease) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 116

Multiple Myeloma (Kahler\'s Disease) - Pipeline by AB Science, H1 2014 117

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Anthera Pharmaceuticals‚ Inc., H1 2014 118

Multiple Myeloma (Kahler\'s Disease) - Pipeline by CureTech Ltd., H1 2014 119

Multiple Myeloma (Kahler\'s Disease) - Pipeline by AVEO Pharmaceuticals, Inc., H1 2014 120

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Janssen Biotech, Inc., H1 2014 121

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Elara Pharmaceuticals GmbH, H1 2014 122

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Zyngenia, Inc., H1 2014 123

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Molecular Templates Inc., H1 2014 124

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 125

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Gliknik, Inc., H1 2014 126

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Celleron Therapeutics Ltd, H1 2014 127

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Immunovative Therapies, Ltd.., H1 2014 128

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Targazyme, Inc., H1 2014 129

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Advancell, H1 2014 130

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2014 131

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Igenica, Inc., H1 2014 132

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Selvita S.A, H1 2014 133

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 134

Multiple Myeloma (Kahler\'s Disease) - Pipeline by APIM Therapeutics AS, H1 2014 135

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Kancera AB, H1 2014 136

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Jasco Pharmaceuticals, LLC., H1 2014 137

Multiple Myeloma (Kahler\'s Disease) - Pipeline by OncoPep Inc., H1 2014 138

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 139

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Formula Pharmaceuticals, Inc., H1 2014 140

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 141

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Modulation Therapeutics, Inc., H1 2014 142

Multiple Myeloma (Kahler\'s Disease) - Pipeline by AbbVie Inc., H1 2014 143

Multiple Myeloma (Kahler\'s Disease) - Pipeline by cCAM Biotherapeutics Ltd., H1 2014 144

Multiple Myeloma (Kahler\'s Disease) - Pipeline by BioNovion B.V., H1 2014 145

Multiple Myeloma (Kahler\'s Disease) - Pipeline by Senhwa Biosciences, H1 2014 146

Assessment by Monotherapy Products, H1 2014 147

Assessment by Combination Products, H1 2014 148

Number of Products by Stage and Target, H1 2014 151

Number of Products by Stage and Mechanism of Action, H1 2014 159

Number of Products by Stage and Route of Administration, H1 2014 166

Number of Products by Stage and Molecule Type, H1 2014 169

Multiple Myeloma (Kahler\'s Disease) Therapeutics - Recent Pipeline Updates, H1 2014 422

Multiple Myeloma (Kahler\'s Disease) - Dormant Projects, H1 2014 551

Multiple Myeloma (Kahler\'s Disease) - Dormant Projects (Contd..1), H1 2014 552

Multiple Myeloma (Kahler\'s Disease) - Dormant Projects (Contd..2), H1 2014 553

Multiple Myeloma (Kahler\'s Disease) - Dormant Projects (Contd..3), H1 2014 554

Multiple Myeloma (Kahler\'s Disease) - Dormant Projects (Contd..4), H1 2014 555

Multiple Myeloma (Kahler\'s Disease) - Dormant Projects (Contd..5), H1 2014 556

Multiple Myeloma (Kahler\'s Disease) - Discontinued Products, H1 2014 557

List of Chart

 

Number of Products under Development for Multiple Myeloma (Kahler\'s Disease), H1 2014 27

Number of Products under Development for Multiple Myeloma (Kahler\'s Disease) - Comparative Analysis, H1 2014 28

Number of Products under Development by Companies, H1 2014 29

Number of Products under Investigation by Universities/Institutes, H1 2014 38

Comparative Analysis by Late Stage Development, H1 2014 41

Comparative Analysis by Clinical Stage Development, H1 2014 42

Comparative Analysis by Early Stage Products, H1 2014 43

Assessment by Monotherapy Products, H1 2014 147

Assessment by Combination Products, H1 2014 148

Number of Products by Top 10 Target, H1 2014 149

Number of Products by Stage and Top 10 Target, H1 2014 150

Number of Products by Top 10 Mechanism of Action, H1 2014 157

Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 158

Number of Products by Top 10 Route of Administration, H1 2014 165

Number of Products by Stage and Top 10 Route of Administration, H1 2014 166

Number of Products by Top 10 Molecule Type, H1 2014 167

Number of Products by Stage and Top 10 Molecule Type, H1 2014 168

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *